Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 44,509	$ 43,190	$ 129,411	$ 129,335
In process research and development	15	15	50	60
General and administrative	11,497	12,459	34,775	35,068
Total operating expenses	56,021	55,664	164,236	164,463
Loss from operations	(56,021)	(55,664)	(164,236)	(164,463)
Other expense
Interest income	465	191	989	525
Interest expense	(3,475)	(4,889)	(10,423)	(14,503)
Other income (expense), net	(332)	115	56	721
Total other expense, net	(3,342)	(4,583)	(9,378)	(13,257)
Net loss	(59,363)	(60,247)	(173,614)	(177,720)
Other comprehensive income (loss):
Foreign currency translation	(173)	(64)	(319)	(274)
Unrealized gain (loss) on marketable securities	102	(73)	(311)	(188)
Other comprehensive income (loss)	(71)	(137)	(630)	(462)
Comprehensive loss	$ (59,434)	$ (60,384)	$ (174,244)	$ (178,182)
Net loss per share, basic (in dollars per share)	$ (0.65)	$ (0.80)	$ (2.14)	$ (2.38)
Net loss per share, diluted (in dollars per share)	$ (0.65)	$ (0.80)	$ (2.14)	$ (2.38)
Weighted average common shares outstanding, basic (in shares)	91,181,427	75,001,510	81,304,089	74,592,632
Weighted average common shares outstanding, diluted (in shares)	91,181,427	75,001,510	81,304,089	74,592,632